Takeda Divests its Select Non-Core Assets in the EU and Canada to Cheplapharm for $562M

 Takeda Divests its Select Non-Core Assets in the EU and Canada to Cheplapharm for $562M

Takeda Divests its Select Non-Core Assets in the EU and Canada to Cheplapharm for $562M

Shots:

  • Takeda will receive $562M up front for divesting its non-core prescription pharmaceutical products targeting a variety of therapeutic categories sold predominantly in the EU and Canada
  • The divested portfolio includes Takeda’s CV/ metabolic and anti-inflammatory therapeutic areas along with Calcium. The portfolio generated FY 2019 net sales of ~$260M
  • The divestiture further enables Takeda’s EUCAN to focus on and drive strategic core growth areas. In Apr’2020, Takeda divested EUCAN’s non-core OTC products to Orifarm Group

Click here ­to­ read full press release/ article | Ref: Takeda | Image: Top Employee Institute

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post